BioSpace Movers & Shakers, June 12
TriSalus – Denver-based TriSalus Life Sciences named Scott Davie as chief technology officer. Davie will oversee research and development of the company’s intravascular infusion systems, based on its proprietary pressure-controlled drug delivery approach with SmartValve technology, and the operation, preclinical execution and management of the IP portfolio. Davie will also serve as the site manager for the Westminster, Colorado facility. Prior to joining TriSalus, Davie held various leadership positions at Medtronic, creating and leading teams and technical departments. He has delivered innovative, complex therapeutic and diagnostic systems from concept to market, including implantable cardiac devices, AF ablation systems and diagnostic platforms in hospitals. His regulatory experience includes filings and registrations over 510k, PMA supplements, original PMAs, and CE marks.
Akcea Therapeutics – Kia Motesharei has been named senior vice president of business development and corporate strategy for Akcea Therapeutics. In this role, Motesharei will drive Akcea’s business development activities and further improve corporate strategy in collaboration with the Akcea leadership team. Motesharei joins Akcea after six years at Merck KGaA, where he most recently served as global head of licensing and business development, neurology and immunology. Prior to joining Merck KGaA, he was Vice President of Business Development & Alliance Management at Dyax Corp., which was acquired by Shire and then by Takeda. Prior to that, Motesharei was Chief Business Officer at French biotech company Genfit and Vice President of Corporate Development at ActivX.
Amplyx Pharmaceuticals – Chris LeMasters has been named Chief Operating Officer and Carlos Sattler has been named Head of Clinical Development for Amplyx Pharmaceuticals in San Diego. As COO, LeMasters will lead operations and corporate development and lead the company’s finance and administrative functions. Prior to joining Amplyx, LeMasters was Chief Business Officer of Mirati Therapeutics, where he led the company’s successful expansion and growth. Sattler joins Amplyx as Senior Vice President, Clinical Development, where he will lead the clinical development program for the company’s novel, world-class antifungal candidate, Fosmanogepix. Before joining Amplyx, Sattler held various management positions at companies such as Halozyme, Sandoz and Merck.
Saluda Medical – Australia-based Saluda Medical Pty Limited has named Jim Schuermann as President and Robert Gaffney as Chief Operating Officer. Schuermann and Gaffney report to Chief Executive Officer John Parker. As President, Schuermann will be responsible for the global commercial and clinical strategy and the implementation of corporate goals. As COO, Gaffney will be responsible for the manufacture, operations and product development of Saluda Medical. Before joining Saluda, Schuermann was CBO at Avedro, which was taken over by Glaukos in 2019. Prior to Avedro, he was Head of Sales and Marketing at HeartWare. Gaffney’s previous experience includes senior management roles in multiple startups and established companies, including President and CEO of SacraMed, Operations Manager at InCube Labs, COO of Spinal Modulation and Vice President of Operations at Satiety.
Amolyt Pharma – Piere Legault has been appointed director and chairman of the board of Amolyt Pharma in France. In addition to his work at Amolyt Pharma, Legault is also chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma. He is the lead director of Urovant Sciences and a board director of Syndax Pharmaceuticals. He was a board director for more than fifteen other biopharmaceutical and pharmaceutical companies. Legault was the CEO of Prosidion and served as CFO and Treasurer of OSI Pharmaceuticals.
Lyndra Therapeutics – Örn Almarsson has been named CTO of Lyndra Therapeutics. As CTO, Almarsson will oversee discovery and product development, while Lyndra will use its platform to develop several new therapies. Almarsson, who most recently led the dispensing science team at Moderna Therapeutics that developed its COVID-19 vaccine delivery system, has extensive experience in pharmaceutical research and development, product design and evaluation with an emphasis on implementing new concepts for drug delivery in clinical trials. Prior to Moderna, he was Vice President of Pharmaceutical Research and Development at Alkermes.
Confo Therapeutics – Rob Scott has been appointed to the Board of Directors of Belgium-based Confo. Scott’s career spanned 30 years of drug discovery and development leadership in the global pharmaceutical and biotechnology industries, including his most recent role as CMO and Head of Development at AbbVie. Prior to AbbVie, he was Global Development TA Head and Head of Development Design Center at Amgen. He is a board member of Transclerate and a member of the PhRMA R & D Leadership Forum.
CellBox solutions – Herbert Mueller-Hartmann has been appointed Head of Research and Development at CellBox Solutions GmbH based in Germany. Mueller-Hartmann was the former head of research and development at Lonza Pharma and Biotech.
MDLIVE – Cynthia Zelis has been named CMO of MDLIVE Inc. Before joining MDLIVE, Zelis held various management positions at university hospitals. Most recently, she was Vice President for Outpatient Operations and Telemedicine.
X4 Pharmaceuticals – Renato Skerlj has been named Chief Scientific Officer of X4 Pharmaceuticals in Cambridge, Massachusetts. Skerlj is one of the scientific founders of X4 and co-inventor of X4’s leading drug candidate mavorixafor. He joined the company in September 2019 as Head of Research and Development. As CSO, Skerlj will lead all research and development functions as well as pre-clinical development activities. Prior to joining X4, Skerlj held a leadership role in drug discovery and development at Lysosomal Therapeutics. Previously, he was Interim Head of Small Molecule Discovery at Genzyme and part of the executive team at AnorMED, a company that was acquired by Genzyme in 2006.